GENERATION HD1

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease.

Approved information available in German only: follow this LINK

Status: recruiting completed.

See also the information on clinicaltrials.gov